



To the Copenhagen Stock Exchange
Announcement No. 10-07 / Copenhagen 12 April 2007

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

www.topotarget.com

TopoTarget Announces New Preclinical Results with Belinostat to be presented at AACR Annual Meeting

Copenhagen, 12 April 2007, TopoTarget A/S (CSE:TOPO) announced today that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, will be presented at the upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in Los Angeles, April 14-18, 2007. A total of five poster presentations on belinostat (PXD101) will be made during the conference.

Belinostat (PXD101), HDAC inhibitor for the treatment of cancer:

- "Activity of PXD101, an HDAC inhibitor, used alone or in combination with 5-FU in preclinical gastroesophageal studies," (Abstract #691) during the conference's HDAC Inhibitors I poster session on Sunday, April 15th in the Exhibit Hall on Poster Board #14
- "Gene expression screen in cell panel selected for varying sensitivity towards the Histone Deacetylase inhibitor (HDACi) PXD101 reveals potential predictors of HDACi sensitivity," (Abstract #687) during the conference's HDAC Inhibitors I poster session on Sunday, April 15th in the Exhibit Hall on Poster Board #10
- "The effect of the histone deacetylase inhibitor (HDACi) PXD101 on cell growth and expression of viral and host genes in hepatitis B virus (HBV)-carrying hepatocellular carcinoma (HCC) cell lines," (Abstract #696) during the conference's HDAC Inhibitors I poster session on Sunday, April 15th in the Exhibit Hall on Poster Board #19
- "The histone deacetylase (HDAC) inhibitor PXD101 suppresses bladder cancer cell growth both in-vitro and in-vivo," (Abstract #2211) during the conference's Mouse Models of Cancer 2: Therapeutic Approaches poster session on Monday, April 16th on Poster Board #9
- "The HDAC inhibitors romidepsin and PXD101 interact synergistically with Bortezomib in human chronic lymphocytic leukemia (CLL) cells in association with NF- κ B inactivation," (Abstract #1835) during the conference's Targeted Agents and Other Novel Therapies poster session on Monday, April 16th on Poster Board #21



TopoTarget A/S

For further information, please contact:

Dr. Peter Buhl Jensen	Telephone	+45 39 17 83 41
Chief Executive Officer	Mobile	+45 21 60 89 22

Background information

About Belinostat (PXD101)

Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including 5-FU, carboplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade® (bortezomib) for Injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes and have been shown to: arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents.

Intravenous belinostat is currently being evaluated in multiple clinical trials as a potential treatment for multiple myeloma, T- and B-cell lymphomas, AML, mesothelioma, liver, colorectal, ovarian cancers, either alone or in combination with anti-cancer therapies. An oral formulation of belinostat is also being evaluated in a Phase I clinical trial for patients with advanced solid tumors. In August 2004, CuraGen signed a Clinical Trials Agreement with the NCI under which the NCI will sponsor several clinical trials to investigate belinostat for the treatment of various cancers, both as a single-agent and in combination chemotherapy regimens. In May 2005, TopoTarget announced the signing of a Cooperative Research and Development Agreement (CRADA) with the NCI to conduct preclinical and nonclinical studies on belinostat in order to better understand its anti-tumor activity and to provide supporting information for clinical trials.

About TopoTarget

TopoTarget (OMX – The Nordic Exchange: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK, Germany and the USA, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer enzyme regulators (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule preclinical drug candidates and seven drugs are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™ is TopoTarget's first product on the market. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing. For more information, please refer to Hwww.topotarget.com.H

TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: the risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from nonclinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products,



TopoTarget Announces New Preclinical Results with Belinostat to be presented at AACR Annual Meeting

processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

